Diseases of the Nervous System Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Diseases of the Nervous System clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Myasthenia GravisMuscle WeaknessAutoimmune Diseases+4 more
Arcellx, Inc.30 enrolled13 locationsNCT06626919
Recruiting
Not Applicable

JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders

Autoimmune Diseases of the Nervous System
Tongji Hospital20 enrolled1 locationNCT06797024
Recruiting

Biomarkers in Autoimmune Disease of Nervous System

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+8 more
Tongji Hospital50,000 enrolled1 locationNCT06502015
Recruiting
Early Phase 1

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+7 more
Tongji Hospital36 enrolled1 locationNCT04561557
Recruiting

Predictors and Prognostic Factors of Myasthenia Gravis Outcome

Myasthenia GravisThymomaNervous System Diseases+6 more
Assiut University30 enrolled1 locationNCT05214612
Recruiting
Not Applicable

Acceptability of Exoskeleton Assisted Walking for Persons With Mobility Issues Due to Multiple Sclerosis

Pathologic ProcessesMultiple SclerosisAutoimmune Diseases+3 more
Sheffield Teaching Hospitals NHS Foundation Trust24 enrolled1 locationNCT04786821
Recruiting

AnovaOS Network Powered Patient Registry

NeoplasmsDiseases of the Circulatory SystemInfectious Disease+18 more
Anova Enterprises, Inc100,000 enrolled1 locationNCT05013944
Recruiting
Phase 3

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

Demyelinating DiseasesMultiple SclerosisNervous System Diseases+3 more
Amsterdam UMC, location VUmc200 enrolled1 locationNCT05834855